/S vs EVLA
(SMD, 0.04; 95% CI, e0.14 to 0.22;
I2 ¼ 40.6%)

B (rated down owing to
imprecision owing to small
sample size)

Total AEs

10 studies, 8 RCTs, 2
observational (1617 patients)
12 studies, 7 RCTs, 5
observational (3390 patients)
7 studies, 6 RCTs, one
observational (2274 patients)

HL/S vs RFA
(RR, 1.65; 95% CI, 1.16 to 2.35;
I2 ¼ 72.5%)
HL/S vs EVLA
(RR, 0.99; 95% CI, 0.77 to 1.27;
I2 ¼ 74.6%)
HL/S vs UGFS
(RR, 0.70; 95% CI, 0.58 to 0.85;
I2 ¼ 28.3%)

C (rated down owing to
inconsistency and risk of
bias)
C (rated down owing to
inconsistency and risk of
bias)
B (rated down owing to risk of
bias)

Key Question 3. Endovenous thermal ablation vs nonthermal ablation
Anatomic closure at
1 year

3 studies, 2 RCTs, one
observational (448 patients)

EVLA vs UGFS
(RR, 1.23; 95% CI, 1.11 to 1.37;
I2 ¼ 0.00%)

Reintervention at
1 year

2 studies, 2 RCTs (740 patients) (RR, 0.51; 95% CI, 0.28 to 0.91;
I2 ¼ 0.00%)

B (rated down owing to risk of
bias)

Total AEs

2 RCTs (710 patients)
One observational study
(60 patients)

C (rated down owing to risk of
bias and inconsistency)
C (rated down owing